- Home
- IBRX vs HP Comparison
IBRX vs HP Comparison
Compare IBRX & HP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- HP
- Stock Information
- Founded
- IBRX 2014
- HP 1920
- Country
- IBRX United States
- HP United States
- Employees
- IBRX N/A
- HP N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- HP Oil & Gas Production
- Sector
- IBRX Health Care
- HP Energy
- Exchange
- IBRX Nasdaq
- HP Nasdaq
- Market Cap
- IBRX 2.3B
- HP 2.4B
- IPO Year
- IBRX N/A
- HP N/A
- Fundamental
- Price
- IBRX $2.26
- HP $26.89
- Analyst Decision
- IBRX Strong Buy
- HP Hold
- Analyst Count
- IBRX 6
- HP 12
- Target Price
- IBRX $9.83
- HP $23.55
- AVG Volume (30 Days)
- IBRX 9.4M
- HP 1.4M
- Earning Date
- IBRX 11-10-2025
- HP 11-17-2025
- Dividend Yield
- IBRX N/A
- HP 3.72%
- EPS Growth
- IBRX N/A
- HP N/A
- EPS
- IBRX N/A
- HP N/A
- Revenue
- IBRX $56,600,000.00
- HP $3,428,058,000.00
- Revenue This Year
- IBRX $629.94
- HP $38.43
- Revenue Next Year
- IBRX $109.91
- HP $3.25
- P/E Ratio
- IBRX N/A
- HP N/A
- Revenue Growth
- IBRX 4227.22
- HP 25.92
- 52 Week Low
- IBRX $1.83
- HP $14.65
- 52 Week High
- IBRX $5.88
- HP $37.46
- Technical
- Relative Strength Index (RSI)
- IBRX 39.09
- HP 72.02
- Support Level
- IBRX $2.30
- HP $24.61
- Resistance Level
- IBRX $2.67
- HP $27.49
- Average True Range (ATR)
- IBRX 0.12
- HP 0.92
- MACD
- IBRX -0.02
- HP 0.17
- Stochastic Oscillator
- IBRX 1.19
- HP 87.62
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About HP Helmerich & Payne Inc.
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies that are intended to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. The Company focus on the drilling segment of the oil and gas production value chain. Company operates in North America, Gulf of Mexico, and other international places such as Argentina, Australia, Bahrain, Colombia and the United Arab Emirates (UAE). Also own and operates a limited number of commercial real estate properties located in Tulsa, Oklahoma. It's real estate investments include a shopping center and of undeveloped real estate projects.